

ABOUT AUMAPHARMA – WHAT WE DO AND WHAT MOTIVATES US

Our mission: Bringing treatments to patients with pulmonary disease.

Aumapharma is a US based startup company with expertise in respiratory diseases and therapeutics. We have two areas of focus:

1. Consultancy to the pharmaceutical industry and academic researchers.
2. Identification and clinical development of drug opportunities that address unmet medical needs.



EXPERTISE

Aumapharma brings versatile, in depth experience in the areas of pulmonary drug development with a particular focus on cystic fibrosis, asthma, COPD and pulmonary fibrosis. In addition, Aumapharma possesses expertise in the area of intensive care, neonatology and antiinfectives.

Aumapharma has an extensive expertise with aerosolized products and has been involved with successful drug developments in the US (FDA) as well as in Europe (EMA, BfArM).

CONSULTING SERVICES

Consulting advice is available on the following topics:

- Intellectual property
- Funding avenues
- Contacts to Venture Capitalists
- Drug Identification
- Regulatory and clinical strategy
- Drug formulation
- Device development
- Consolidated development plans

Aumapharma is also available to advise on building a team to design and conduct preclinical and clinical studies, including phase 1, phase 2 and pivotal, phase 3 studies. The team members will include representatives for regulatory, clinical operations, preclinical studies, CRO outsourcing, manufacturing, project management and marketing.

CONTACT

Thomas Hofmann, MD PhD
CEO, Founder Aumapharma Inc.
215 Decatur Street
Doylestown, PA 18901

Phone: 215-345-4150
Cell: 267-884-3042
www.aumapharma.com



PHARMA DEVELOPMENT OPPORTUNITIES

Aumapharma is building a startup pharmaceutical company with a focus on profitably developing and obtaining regulatory approval for new products to treat significant unmet medical needs for respiratory conditions. The initial focus is on reformulation, delivery device development, safety and dosage testing, efficient clinical trial design and regulatory approvals with existing, known compounds. We believe that unmet medical needs in pulmonary indications are commercially attractive and that we can serve those needs by utilizing formulation, drug delivery and clinical development expertise.

Our goal is to become a leading provider of respiratory disease directed products. We intend to accomplish this goal by building an organization that develops and obtains regulatory approvals for small molecule drugs for various respiratory conditions with unmet clinical need, thereby creating better disease management options, improved human health and superior quality of life for our patients.

Focus of Aumapharma development:

- Development expertise in pulmonary delivery in orphan indications that are overlooked by Big Pharma
- Development of orphan indications in partnership with opinion leaders and patient advocacy groups
- Develop existing, academic IP and investigator INDs that are explored by academics from US/Europe
- Utilize knowledge of targeted pulmonary delivery: Aumapharma is in a unique to rapidly develop pulmonary drugs by utilizing the deposition efficacy of novel technologies
- Aumapharma has global contacts in the area of pulmonary drug development and can leverage its worldwide business contacts in this space
- Aumapharma will operate both in the US as well as Europe

